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1 ABSTRACT 
 
Vascular endothelial growth factors constitute a family of polypeptides, VEGF-A, -B,   
-C, -D and PlGF, that regulate blood and lymphatic vessel development upon binding 
to three types of receptors, VEGFR-1 -3. Pox viruses of the Orf family encode highly 
related proteins called VEGF-E that show only 25 % amino acid identity with VEGF-A 
but bind with almost the same affinity to VEGFR-2. The crystal structure studies 
showed distinct conformational differences between VEGF-E and the other VEGF’s in 
the loops L1 and L3 which presumably determine receptor specificity. To further 
investigate the determinants of receptor specificity selected segments in L1 and L3 
between VEGF-E and PlGF were exchanged. The mutated proteins were produced in 
the yeast Pichia pastoris and purified over nickel affinity and size exclusion 
chromatography. Binding assays on PAE cells expressing either VEGFR-1 or -2 
confirmed that these loops determine receptor specificity. The loop chimera of   
VEGF-E where both the loops L1 and L3 were exchanged showed specific binding to 
VEGFR-1 and was crystallized. However, crystal structure determination was not 
possible due to poor crystal quality.  
Moreover, preliminary expression tests of selected VEGFR-2 domains in E.coli failed 
to provide protein of suitable quality for future crystallographic studies of ligand-
receptor complexes.  
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2 INTRODUCTION 
 
2.1 Angiogenesis 
 
Angiogenesis, or formation of new blood capillaries from preexisting vessels, is an 
important biological process and plays both beneficial and detrimental roles in the 
organism. Physiological angiogenesis occurs during embryogenesis, the female 
reproductive cycle and in wound healing. Abnormally enhanced angiogenic response 
is observed in rheumatoid arthritis, diabetic retinopathy, and during tumor 
development.  
 
Inhibition of the neovasculature was shown to abolish or slow tumor growth in 
various experimental models. On the other hand, promotion of the angiogenic 
response can prove beneficial in the treatment of ischemic conditions, such as 
myocardial ischemia/ infarction. It is therefore obvious, that the ability to prevent 
and treat many of these diseases relies on our understanding of the molecular 
mechanisms underlying the angiogenic response.  
 
Angiogenesis is a result of complex interplay of positive and negative regulators. The 
VEGFs (Vascular Endothelial Growth Factors) are molecules that serve as inducers of 
angiogenesis and therefore it is important to know more about the interplay of 
these molecules and their receptors. (Petrova et al., 1999) 
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2.2 VEGF’s and VEGF receptors 
 
There is a consensus that the Vascular Endothelial Growth Factors (VEGFs) are 
crucial for vascular development and neovascularization in physiological and 
pathological processes in both embryo and adult. More recent data indicate 
essential roles for the VEGFs in haematopoietic cell function and in lymph 
angiogenesis. VEGF has also been implicated in pathological angiogenesis 
associated with tumors, intraocular neovascular disorders and other conditions. 
VEGF denotes a family of homodimeric glycoproteins, which currently consists of 
five mammalian members VEGF-A, -B, -C, -D and placenta like growth factor (PlGF), 
Orf virus-encoded VEGF-like proteins called VEGF-E and a series of snake venoms 
collectively called VEGF-F. Due to alternative splicing or posttranslational processing, 
PlGF, VEGF-A, -B, -C and –D are generated in a number of functionally distinct 
isoforms. The biological function of VEGF is mediated through binding to three 
tyrosine kinase receptors, VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk-1) and VEGFR-3 (Flt-4) 
that are localized on the cell surface of endothelial cells, in bone-marrow derived 
hematopoietic precursor cells and in malignant cells. VEGFs bind, in an overlapping 
pattern, to the different VEGF receptor tyrosine kinases (Figure 1). The role of each 
receptor-ligand interaction remains to be precisely defined but knockout studies 
indicate that VEGFR-1 plays different roles, negative and regulatory, in angiogenesis. 
VEGFR-2 is the main signal-transducing VEGF receptor for mitogenesis of endothelial 
cells and VEGFR-3 is involved in angiogenesis of the lymphatic vasculature. (Cross et 
al., 2003) 
 
 
 
 
Figure 1. Schematic illustration of vascular endothelial growth factor receptor expression patterns and 
ligand specificity. The VEGF ligand family includes VEGF-A, -B, -C, -D, -E and PlGF, which all bind in a 
specific manner to three different receptor tyrosine kinases, VEGFR-1, -2 and -3. VEGFR-1 and its 
ligands are yellow, VEGFR-2 and its ligands are blue, and VEGFR-3 and its ligands are green. Ligands 
shaded in two colors bind to more than one receptor type. Both PlGF and VEGF-B are selective ligands 
for VEGFR-1, whereas VEGF-E is a selective ligand for VEGFR-2. In contrast, all VEGF-A isoforms bind to 
both VEGFR-1 and VEGFR-2.  
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The VEGF receptors 1-3 belong to the class III receptor tyrosine kinases of the platelet-
 VEGFR-2 and its ligand VEGF-E 
o clarify the biological functions driven by each VEGFR one needs receptor specific 
e of sequence 
A and PlGF in their free 
tal structure of VEGF-E 
vealed high similarity to the known structural 
derived growth factor (PDGF) receptor subfamily which is characterized by the 
presence of seven immunoglobulin homology domains in their extracellular, ligand-
binding part and an intracellular tyrosine kinase domain split by a kinase insert. 
Ligand binding is thought to induce homodimerization of the VEGF receptors and 
transphosphorylation of their intracellular domains, which allows the activation of 
complex intracellular signaling pathways. The VEGF molecule represents an 
antiparallel disulfide-linked homodimer which interacts with the receptor via 
binding sites at the poles of each molecule. As a result of domain deletion studies of 
VEGFR-1 and VEGFR-2 it was shown that ligand binding function is localized to the 
second and third Ig domain, but the two domains play different roles in the VEGFR-1 
and VEGFR-2 interaction with the VEGFs. (Ferrara et al, 2003; Petrova et al., 1999) 
 
 
 
2.3
 
T
proteins. Orf viruses encode for a VEGF-like protein that specifically binds at high 
affinity and activates VEGFR-2. Orf viruses, the type species of the parapoxvirus 
genus, belong to the parapoxvirus family and produce a postular dermatitis in 
sheep, goats and humans. Several reports have described prominent vascular 
changes associated with lesions caused by Orf virus. Lesions produced after infection 
show extensive proliferation of vascular endothelial cells, dilation of blood vessels 
and dermal swelling. This is apparently due to the fact, that Orf virus encodes a 
homolog of mammalian vascular endothelial growth factor (VEGF-A). 
The proteins encoded by these sequences show an extraordinary degre
variation and are collectively called VEGF-E. They have been found in more than 20 
independent parapoxvirus isolates. The coding sequence for these proteins was 
apparently captured from a mammalian host and the sequence variation reflects 
numerous cycles of mutation and genetic recombination. VEGF-E family members 
show only 20-25% amino acid identity with VEGF-A but bind with almost the same 
affinity as VEGF-A to VEGFR-2. VEGF-E ligands lack a heparin-binding domain yet 
retain binding to neuropilin, a co-receptor for VEGFRs that is essential for proper 
vascular development. VEGF-E variants are potent mitogens stimulating 
proliferation of human endothelial cells in vitro and vascularization of sheep skin in 
vivo with potencies equivalent to VEGF-A. (Wise et al., 2003) 
Structural studies of the receptor binding domains of VEGF-
and receptor-bound form have been reported previously and the crystal structures of 
these ligands in complex with the minimal ligand binding fragment (Ig-like domain 
2) of VEGFR-1 are known. (Christinger et al, 2003; Iyer, S. et al, 2001; Muller, Y. A. et al, 
1997; Starovasnik, M. A. et al, 1999; Wiesmann, C., et al, 1997) 
Recently, Pieren and co-workers at PSI determined the crys
(NZ2 variant). (Pieren et al., 2005) 
The structure of VEGF-E Nz2 re
homologs VEGF-A, PlGF and the snake venoms Vammin and VR-1, which are all 
dimeric and fold into the common cystein knot structure. Distinct conformational 
differences were observed in the loops L1 and particularly in L3 which presumably 
determine receptor specificity (Figure 2). 
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Loop-3 of VEGF-E contains a highly flexible GS-rich motif that differs from L3 in all 
other structural homologs. However, none of these structural features are 
exclusively shared with the other receptor 2 specific ligands.  
 
 
 
igure 2. Comparison of VEGF-E with other structural homologs. Superposition in stereo of the Cα-
utation studies with VEGF-A showed that single amino acids in these loops are 
ue to structural comparison and binding assays with different mutants it is 
 
F
traces (112 Cα atoms) of VEGF-A (green), VEGF-A-D2 (olivegreen), PlGF (orange), PlGF-D2 (yellow), 
Vammin (red), VR-1 (salmon) and VEGF-E NZ2 (blue). In VEGF-E loop L3 is twisted away from all other 
observed conformations.  
 
 
 
M
essential for the binding of VEGF-A to VEGFR-2. Mutations of these amino acids give 
rise to much weaker interactions. Although these residues are not conserved in 
VEGF-E it binds to VEGFR-2 with high affinity.  
 
D
supposed that the molecular basics of the binding and specifity of the VEGF’s to the 
different receptors lie in the structural parameters of loop-1 and loop-3. 
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2.4
 
 Goal of the diploma thesis 
he comparison of the crystal structures of PlGF, VEGF-A and VEGF-E showed that 
iploma work. The aim was to 
ned to show how 
ost important 
s an option, a selected VEGFR-2 fragment, which contains the minimal binding 
T
the distinct conformational differences are in loop-1 and loop-3. It has to be 
answered if these are critical determinants for receptor affinity and if this might be 
the reason why VEGF-E only binds to VEGFR-2. Therefore I created different VEGF-E 
loop mutants during my semester thesis. In two constructs I replaced either loop-1 or 
loop-3 by the one from PlGF, which only binds to VEGFR-1, and in a third construct, I 
changed both of this loops with the ones of PlGF. Finally, I inserted a point mutation 
in loop-1 of a wildtype VEGF-E, so that the DNA sequence encodes no longer for the 
amino acid arginine but for isoleucine. Arginine 46 is able to form a salt bridge to 
glutamate 64 in loop-2. This salt bridge eventually blocks the gateway to VEGFR-1. I 
succeeded in generating three of these four mutants. 
During the semester thesis arose the goal for my d
generate and characterize the fourth of this VEGF-E mutant, the L13-mutant. The 
practical work consisted in cloning, protein expression in Pichia pastoris and 
purification by nickel affinity chromatography and gel filtration. The other three 
mutants have already been produced by someone else in the lab.  
Moreover, functional assays with this purified proteins were plan
the different mutations affect the binding of VEGF-E to VEGFR-1 or -2. 
Finally, depending on the outcome of the binding assays, the m
mutants had to be crystallized. The structure determination should reveal more 
details about the conformational change that might occur through the mutations. 
 
A
domains for VEGF-A and –E, could be cloned for expression in E.coli. The aim of this 
additional project was to speed up the production of functional VEGFR-2 domains for 
future crystallographic studies of ligand-receptor complexes.  
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3 MATERIALS AND METHODS 
 
3.1 VEGF-E-L13-Mutant 
3.1.1 Cloning of VEGF-E-L13-Mutant by Site Directed Mutagenesis 
 
Table 1 Scheme for the PCR Reaction 
 Sample Reaction Positive Control Reaction Negative Control 
Reaction 
template 
(expression clone) 
30 ng 
0.3 µl  
(VEGF-E-L1) 
0.5 µl 
(VEGF-A121) 
0.5 µl 
(VEGF-A121) 
primer forward F3 (1:10) 
125 ng 
1 µl 1 µl (5’AOX) -- 
primer reverse R3 (1:10) 
125 ng 
1 µl 1 µl (3’AOX) -- 
dNTPs [10 mM] 1 µl 1 µl 1 µl 
buffer 5x 
F-518 (FINNZYMES) 
10 µl 10 µl 10 µl 
H2O 35 µl 35 µl 37 µl 
polymerase phusion 
(F-530L, FINNZYMES) 
1 µl 1 µl 1 µl 
Total 50 µl 50 µl 50 µl 
 
A sequenced VEGF-E-L1-mutant construct (PCR Gateway® Technology: expression 
clone) that contains loop-1 of PlGF was used as template for the sample reaction. 
This mutant is a chimera of VEGF-E and loop-1 of human PlGF.  
 
The primers (F3; R3) are specific for this reaction and have the following sequences 
(Microsynth): 
 
Forward primer, F3: 
5’- GTAAACGTGAGCATGGAACTCCTGAAGATCCGTTCTGGGGACCGGAACGGGATGCAACGTCTGAGC-3’  
                                                                    82   K       I       R     S       G      D      R   88 
TM     56.7°C        58.7°C 
 
Reverse primer, R3 
5’- GCTCAGACGTTGCATCCCGTTCCGGTCCCCAGAACGGATCTTCAGGAGTTCCATGCTCACGTTTAC-3’ 
TM     58.7°C        56.7°C 
 
Table 2 PCR-Conditions 
Segment Cycles Temperature Time 
1 1 98°C 2'30'' 
98°C 30'' 
62°C 30'' 
2 
  
  
20 
  
72°C 2'30'' 
  hold 10°C   
 
After the PCR 1 µl of the enzyme DpnI (Fermentas; 10 u/µl, 2500 u) was added to the 
samples and the mix was incubated for 3 hours at 37° C. This digest was done to 
degrade the template DNA. 
The samples were then purified by MinElute PCR Purification Kit and eluted in 15 µl 
water. 
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3.1.2 Electroporation in E.coli 
 
100 µl cells (Top10, electrocompetent) were thawed on ice and mixed with 400 µl of 
10 % glycerol. 60 µl of this cell suspension were mixed with 4 µl of purified DNA and 
immediately electroporated using the following conditions: 200 Ohm, 1.7 kV, 25 uF, 
which gave about 4.0-4.5 ms pulse time. Immediately after pulse 400 µl low salt LB 
media were added and the mixture was transferred into a 5 ml Snap cap. Upon 1 
hour incubation at 37° C by shaking at 200 rpm, 150 µl culture were spreaded on low 
salt LB Agar plates with ZeocinTM [25 µg/ml] and incubated over night at 37° C. 
 
3.1.3 Miniculture and Miniprep 
 
Miniculture: 
 
Single colonies were picked from the plates with a sterile toothpick to inoculate over 
night cultures in 5 ml low salt LB media with ZeocinTM [25 µg/ml] at 37° C and 200 
rpm.  
 
Miniprep: 
 
The over-night cultures were centrifuged for 10 min at 4° C and 3000 xg (Eppendorf 
Centrifuge 5810R). The supernatant was discarded and the pellets resuspended in 
300 µl cold buffer P1 (50 mM Tris pH 8, 10 mM EDTA, 0.1 mg/ml RNase A). 300 µl of 
buffer P2 (200 mM NaOH, 1% SDS) were added and the mixture was incubated for 5 
min at RT. Upon addition of 300 µl of cold buffer P3 (3M KCOOCH3, pH 5.5) the 
mixture was incubated for 10 min on ice and subsequently centrifuged for 10 min at 
4° C and 11’000 xg (Eppendorf Centrifuge 5415R). The supernatant, which contained 
the plasmid in solution, was transferred to new 2 ml-tubes. 700 µl isopropanol 
(100%) were then added and the mixture was incubated for 5–10 min at RT before 
centrifugation for 15 min at RT and 11’000 xg (Eppendorf Centrifuge 5415R). The 
supernatant was discarded and the pellet (plasmid DNA) was washed twice with 
70% ethanol. Finally the pellet was dried and resuspended in 40 µl H2O. 
 
3.1.4 Restriction Digest 
 
The samples were digested with the enzymes Afl III (New England Bio Labs, 5 u/µl) 
and Eco24I (Fermentas; 10 u/µl, 1500 u). The following buffers were used: for Afl III 
buffer H (SuRE Cut Buffer H for Restriction Enzymes, 10x conc., Roche) and for Eco 24I 
buffer B (SuRE Cut Buffer B for Restriction Enzymes, 10x conc., Roche).  
 
Table 3 Scheme for the restriction digest 
restriction enzyme 0.5 µl 
buffer 1 µl 
H2O 4.5 µl 
DNA 4 µl 
Total 10 µl 
 
The samples were incubated at 37° C for 2 hours and analyzed on a 1 %-agarose gel.  
 9
Diploma Thesis                                                                                                                              MATERIALS AND METHODS  
Katrin Biedermann 
3.1.5 EasyCompTM Transformation into Pichia pastoris 
 
For transformation into P. pastoris the plasmid DNA had to be linearized. 
 
Table 4 Linearization of the plasmid DNA (restriction digest) 
DNA (7 µg/µl) 10 µl  
buffer Sac I+
(SuRE Cut Buffer A for 
Restriction Enzymes, 10x 
conc., Roche) 
15 µl 
Sac I  
(Fermentas 10 u/µl, 1200 u) 
5 µl 
H2O 120 µl 
Total 150 µl 
 
3 µg of linearized Pichia expression vector DNA was added to 50 µl of competent 
cells (freshly prepared or frozen competent Pichia cells (X-33)). 1 ml of Solution II was 
added to the DNA/cell mixture and mixed by flicking the tubes. The transformation 
reaction was then incubated for 1 hour at 30° C, and mixed every 15 min by flicking 
the tubes. After heat shock at 42° C for 10 min, the cells were splited into 2 
microcentrifuge tubes and 1 ml of YPD medium was added to each tube. The cells 
were further incubated at 30° C for 1 hour to allow expression of ZeocinTM resistance. 
The samples were then pelleted by centrifugation at 3000 xg for 5 min at RT and the 
supernatant was discarded. Each tube of cells was resuspended in 500 µl of Solution 
III and the cells were combined into one tube. Again the cells were pelleted by 
centrifugation at 3000 g for 5 min at RT and the supernatant was discarded. The 
pellets were resuspended in 100 µl of Solution III and spreaded on low salt LB agar 
plates with ZeocinTM [100 µg/ml]. 
 
3.1.6 Protein expression 
 
Small-scale expression 
Small-scale expression was performed to select for high-expression clones. Positive 
clones were inoculated into 5 ml YPD media containing ZeocinTM [100 µg/ml] for a 
first biomass accumulation. After two days incubation in a shaking incubator with 
200 rpm at 30° C, the cells were harvested by centrifugation at 3000 xg (Eppendorf 
Centrifuge 5810R) for 5 min at RT. The pellet was then resuspended in 100 ml BMGY 
media and further incubated at 30°C in the shaking incubator for another day, so 
that the cultures reached an OD600 = 10. The cells were harvested and the pellets 
were resuspended in 100 ml BMMY media to induce expression. 100 % methanol 
was added to a final concentration of 2 % methanol every 24 hours to maintain 
induction. 1 ml samples of each culture were taken at time points 0, 24, 48 and 72h 
post induction to analyze expression levels and determine the optimal time post 
induction to harvest the supernatant. Protein expression was detected with 
Coomassie-stained SDS-PAGE. 
 
Large-scale expression 
50 ml of YPD media with ZeocinTM [100 µg/ml] were inoculated with the test 
expressing clones and grown in a shaking incubator at 30° C for two days. The 
procedure then was the same as described above but with 1000 ml media instead of 
100 ml. 72 h of induction turned out as the optimal time point to harvest the protein. 
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3.1.7 Preparation of deglycosylated VEGF-E-mutants 
 
Expression was stopped by centrifugation of the cell culture in 1000 ml bottles for 
20 min at 3000 xg and 4° C (SORVALL®RC 3B PLUS). The supernatant was transferred 
to an 1000 ml Erlenmeyer flask and the media was filtered through a 15 µm glass 
fibre prefilter and a 8 µm mainfilter (Millipore) by using a peristaltic pump at 20 
rpm. The filtrate was collected in an 1000 ml Erlenmeyer flask. After the filtration 50 
µl endoglycosidase F1 [2 mg/ml] were added to 500 ml filtrate. The mixture was 
incubated over night at 25° C with low shaking at 60-70 rpm. The next day, the 
medium was filtered again through a 0.45 µm filter (Millipore). 
 
3.1.8 Purification 
3.1.8.1 Nickel affinity chromatography 
 
The first purification step was performed on a Ni2+ -chelating sepharose column 
using an Äkta Prime System (Amersham Pharmacia Biotech). The deglycosylated 
culture supernatant was loaded on the column at a flow rate of 5 ml/min and the 
flow through was collected. The column was then washed with binding buffer        
(10 mM Imidazole, 10 mM Na2HPO4, 10 mM NaH2PO4, 50 mM NaCl) until a baseline 
was reached. After an additional wash step with 25 ml wash buffer (50 mM 
Imidazole, 10 mM Na2HPO4, 10 mM NaH2PO4, 50 mM NaCl) the column bound 
protein was eluted with 30 ml elution buffer (500 mM Imidazole, 10 mM Na2HPO4,   
10 mM NaH2PO4, 50 mM NaCl). The eluted 1 ml-fractions were analyzed on a 15 % 
SDS-PAGE (Coomassie- stained). 
The fractions that contained VEGF-E were pooled and concentrated up to a volume 
of 500 µl in 6 ml VIVASpin concentrator, 10 kDa MWCO at 4° C and 3000 xg 
(Eppendorf Centrifuge 5810R) 
 
3.1.8.2 Gel filtration (Size exclusion chromatography)  
 
This size exclusion chromatography was performed on a Superdex 200 column 
(Amersham Pharmacia Biotech). The column was first equilibrated with buffer           
(50 mM Tris/HCl pH 7.5, 100 mM NaCl) at a flow rate of 0.5 ml/min. The 
concentrated sample was filtered through a 0.22 µm eppendorf filter device and 
loaded onto the column using a 500 µl loop. Fraction collection (0.5 ml fractions) 
started 7 ml after injection.  
 
3.1.9 Competitive Binding Assays 
 
Canine VEGF-A164 (this is the protein corresponding to human VEGF-A165) was 
iodinated with the IODO-GEN method using 0.5 mCi of Na 125I (Amersham Pharmacia 
Biotech, IMS-30) activated for 6 min at RT in a tube coated with 50 µg of Iodogen 
(Pierce) and mixed with 10 µg of deglycosylated VEGF-A164 for 9 min at RT. Reaction 
was stopped with 1 mM DTT. The iodinated protein was then separated from free 
iodine on a PD10 gel filtration column (Amersham Pharmacia Biotech) that was 
equilibrated with 0.5% BSA, 1 mM citric acid in PBS. The resulting specific 
radioactivity was 85’260 c.p.m./ng. Porcine aortic endothelial (PAE) cells expressing 
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VEGFR-1 or VEGFR-2 were grown overnight to subconfluency in 24-well tissue culture 
plates and incubated for 4 hours on ice with 0.1 nM 125I-labeled VEGF-A164 in the 
presence or absence of the indicated amount of cold competitor. Each concentration 
point was done in triplicates. Unbound radioactivity was eliminated by 3 washes 
with MEM, 25 mM HEPES, w/o L-glutamine (Amined) containing 0.25% BSA. Cells 
were lysed in 200 µl 1 M NaOH and the associated radioactivity determined in a 
Beckman γ-counter.  
 
3.1.10 Crystallization and X-Ray diffraction experiments 
 
Crystallization was performed at 20° C using the hanging-drop vapor-diffusion 
method. The drops were prepared by mixing 1 µl of the protein (20 mg/ml in 5o mM 
Tris/HCl, 100 mM NaCl) and 1 µl of the reservoir solution. Each reservoir contained 
200 µl of the precipitant solution. For the first crystallization screen the 
Crystallization Basic Kit for Proteins (SIGMA®) was used, which contains 50 different 
precipitant solutions.   
 
For X-Ray diffraction experiments, crystals were equilibrated stepwise in 
cryoprotectant solution (Table 5) and flash-frozen directly in a liquid-nitrogen cryo 
stream. The measurements were performed either on a in house X-Ray source or at 
the SLS. 
 
 
Table 5 Crystallization buffers and cryoprotectants 
Precipitant solution  Cryoprotectant 
o.2 M Li-Sulfate 
0.1M Tris-HCl pH 8.5 
30% PEG 4K 
+ 5 - 20 % Glycerol 
0.1 M HEPES pH 7.5  
o.8 M Na-K-Tartrate 
+ 5 - 40 % Glycerol 
o.1 M Na-citrate pH 5.6 
20 % Isopropanol 
20 % PEG 4K 
direct, no cryoprotectant needed 
o.1 M HEPES pH 7.5 
10 % Isopropanol 
20 % PEG 4K 
direct, no cryoprotectant needed 
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3.2 VEGFR-2 
3.2.1 Cloning of VEGFR-2_D1-3_C-GST by PCR-Gateway-Technology 
 
Table 6 Amplifying of VEGFR-2_D1-3: an attB-product 
 Sample Reaction Positive Control Reaction Negative Control Reaction 
template  
50 ng 
1.5 µl  
(pPICZα_D1-3) 
1.5 µl 
(pPICZα_D1-3) 
1.5 µl 
(pPICZα_D1-3) 
primer forward (1:20) 
125 ng 
1 µl 1 µl (D2-3) -- 
primer reverse (1:20) 
125 ng 
1 µl 1 µl (D2-3) -- 
dNTPs [10 mM] 1 µl 1 µl 1 µl 
buffer 5x 
F-518 (FINNZYMES) 
10 µl 10 µl 10 µl 
H O 2 35 µl 35 µl 37 µl 
polymerase phusion 
(F-530L, FINNZYMES) 
1 µl 1 µl 1 µl 
Total 50 µl 50 µl 50 µl 
 
To amplify VEGFR-2_D1-3, a pPICZα_D1-3 vector was used as template. The primers 
for this reaction were specifically designed. The following primers were used 
(Microsynth): 
 
Forward primer: 
5’-
GGGGGACAAGTTTGTACAAAAAAGCAGGCTTCGAAGGAGATAGAACCATGGCCTCTGTGGGTTTGCCTAGT
G-3’  
71 nucleotides  ATTB1               SD/ KOZAK  D1 
 
Reverse primer: 
5’- GGGGACCACTTTGTACAAGAAAGCTGGGTCTCCTTGGAAGTATAAGTTTTCTTTTTCATGGACCCTGAC-3’ 
69 nucleotides  ATTB2   TEV    D3 REV 
 
 
Table 7 PCR-Conditions 
Segment Cycles Temperature Time 
1 1 98°C 2’ 
98°C 30'' 
55°C 30'' 
2 
  
  
20 
  
72°C 40'' 
3 1 72°C 2’ 
  hold 10°C   
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3.2.2 BP Recombination Reaction 
 
A BP recombination reaction was performed between an attB-flanked DNA fragment 
and an attP-containing donor vector to generate an entry clone. 
 
Table 8 Scheme of BP Recombination Reaction 
 
 
 Sample Positive Control 
attB-PCR product (100ng) 0.5 µl -- 
pDONRTM vector (150ng/µl) 0.5 µl 0.5 µl 
pEXP7-tet positive control 
(50ng/µl) 
-- 0.5 µl 
BP ClonaseTM Reaction Buffer 5x 1 µl 1 µl 
TE-buffer, pH 8.0 2 µl 2 µl 
BP ClonaseTM enzyme mix 1 µl 1 µl 
Total 5 µl 5 µl 
pDONRTM vector, pEXP7-tet positive control, BP ClonaseTM Reaction Buffer 5x and         
BP ClonaseTM enzyme mix were purchased from the company Invitrogen®. 
 
The reaction was incubated in the thermocycler over night at 25°C. 0.5 µl Proteinase 
K (Invitrogen®) were added and the mix was incubated for 15 min at 37° C.  
 
Electroporation in E.coli, Minipreps, Minicultures and Restriction digest then 
followed as described in 3.1.2 – 3.1.4 (p. 9). 
 
3.2.3 LR Recombination Reaction 
 
A LR recombination reaction was performed between an attL-containing entry clone 
and an attR-containing destination vector to generate an expression clone.  
 
Table 9 Scheme of the LR Recombination Reaction 
 Sample Positive Control 
entry clone  
20-30ng 
2 µl -- 
destination vector (pDEST24), 
100ng 
0.75 µl 0.75 µl 
pENTERTM-gus -- 1 µl 
5x LR ClonaseTM Reaction Buffer 1 µl 1 µl 
TE Puffer, pH 8 0.25 µl 1.25 µl 
LR ClonaseTM enzyme mix 1 µl 1 µl 
Total 5 µl 5 µl 
 
5x LR ClonaseTM Reaction Buffer und LR ClonaseTM enzyme mix were purchased from 
the company Invitrogen®. As entry clone the product of the BP recombination 
reaction was used.  
 
The reaction was incubated in the thermocycler over night at 25°C for. 0.5 µl 
Proteinase K (Invitrogen®) were added and the mix was incubated for 15 min at 37° C. 
 
Electroporation in E.coli, Minipreps, Minicultures and Restriction digest then 
followed as described in 3.1.2 – 3.1.4 (p. 9).  
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3.2.4 Chemical Transformation into E.coli 
 
1 µl LR reaction-mix was added to 75 µl DH5α cells and incubated on ice for 30 min. 
After 45 seconds heat shock at 42° C and 2 min incubation on ice 200 µl SOC-
Medium were added to the mixture, which was further incubated at 37° C for 30 min 
to allow expression of Ampicillin resistance. 100 µl of cell suspension were then 
spreaded on LB agar plates with Ampicillin [50 µg/ml] and incubated over night at 
37° C.  
 
3.2.5 Protein expression 
 
Small-scale expression: 
 
To find out the optimal point to harvest the cells, first a small-scale expression was 
made. Therefore 5 ml of LB media with antibiotics were inoculated and grown over 
night at 37° C and 200 rpm. The next day, 0.5 ml of these suspensions were diluted in 
5 ml fresh LB media with antibiotics. The cultures were grown (37° C and 200 rpm) 
until they reached an OD600 of 0.6 -1.0. Expression was then induced with 1 mM IPTG. 
0.5 ml samples were collected every hour and accordingly analyzed on a 10 % SDS-
PA-gel and with Western Blot. 
 
Large-scale expression: 
 
50 ml of LB media with antibiotics were inoculated and grown over night at 37° C 
and 200 rpm. The next day, the culture was diluted to 1 l LB media and incubated at 
37° C and 200 rpm to reach an OD of 0.6-1.0. To induce expression 1 mM IPTG was 
added and the cultures were incubated for 2-4 hours (depending on the E.coli strain) 
at 30° C. 
 
3.2.6 Dot Blot and Western Blot 
 
Dot Blot (Test for expression and solubility): 
 
250 µl cell suspension were added to 3 ml autoinduction medium (ZYP-5052 after 
F.W. Studier) in 10 ml 24-deepwell plates and incubated over night at 37 °C and 200 
rpm. The next day for each cell suspension a whole cell lysate and a soluble sample 
was prepared and filtrated through a PVDF-membrane using a standard lab 
protocol.  
After this the membrane was blocked with Qiagen blocking buffer for 30 min and 
incubated with an antibody-mix for 1 hour. The first antibody was a polyclonal rabbit 
anti-GST-IgG (100 µg/ml, SantaCruz Biotechnology) and the second one a 
monoclonal goat-anti-rabbit-AP-IgG (200 µg/0.5 ml). The membrane was washed 
with TBS-buffer (20 mM Tris/HCl pH 7.5, 150 mM NaCl) and TTBS-buffer (20 mM 
Tris/HCl pH 7.5, 150 mM NaCl, 0.05 % Tween 20) and developed with NBT/BCIP in AP-
substrate buffer (100 mM Tris/HCl pH 9.5, 100 mM NaCl, 5 mM MgCl2). 
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Western Blot: 
 
A 10 % SDS-PA-gel was run with 30 mA for 1 hour. Then the gel was blotted on a 
PVDF-membrane with 60 mA for 2 hours using a semi-dry transfer buffer system 
(Bio rad). After blotting the membrane was processed as described in the Dot Blot 
procedure.  
 
3.2.7 Preparation of cell lysates  
 
The frozen pellet from 1 l E.coli was resuspended in 24 ml ice cold lysis buffer (50 mM 
Tris/HCl pH 8.0, 150 mM NaCl, 5 mM EDTA, 10 % glycerol, 1 mM PMSF, 1 mM DTT). 1.25 
ml 20 % Triton-X100 was added to final 1 %. Accordingly, 2-5 mg lysozyme was added 
and the mix was left on ice for 1 hour and then sonicated on ice for 30 seconds                     
(o.5’’ on/0.5’’ off, macrotip 65 %). The cell debris were separated by centrifugation 
(27’000 xg;  4° C; 30 min) and the supernatant was used for purification.  
 
3.2.8 Purification by Glutathione Sepharose (affinity chromatography) 
 
The clear lysate was applied twice to the glutathione-sepharose-column by gravity 
flow and the flow through was collected. The column was washed with 50 ml wash 
buffer (50 mM Tris/HCl pH 8.0, 1 M NaCl, 5 mM EDTA, 10 % glycerol, 0.1 % Triton X-
100, 1 mM DTT) and the wash fraction was collected. 15 ml of elution buffer (50 mM 
Tris/HCl pH 8.0, 150 mM NaCl, 5 mM EDTA, 10 % glycerol, 1 mM DTT, 1 mM reduced 
glutathione) were added to the column to elute the protein and 1 ml fractions were 
collected. The fractions were analyzed on a 10 % SDS-PAGE. 
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4 RESULTS 
 
4.1 VEGF-E-L13 
 
A VEGF-E-L13-mutant was cloned and transformed into the yeast P. pastoris for 
expression as a secreted protein. The protein was purified by nickel affinity and size 
exclusion chromatography. The purified protein was used for binding assays and 
crystallization screens.  
4.1.1 Cloning of VEGF-E-L13-Mutant by Site Directed Mutagenesis 
 
Positive VEGF-E-L13 clones were analyzed by restriction digest with the restriction 
enzymes Afl III and Eco24I. Compared to the template DNA (pPICZαA-VEGF-E-L1) of 
the cloning reaction the pPICZαA-VEGF-E-L13 shows a different restriction pattern.  
Figure 3 shows the result of a restriction digest with different positive VEGF-E-L13 
clones and as negative control VEGF-E-L1 on a 1 % agarose gel. The restriction enzyme 
Eco24I linearizes VEGF-E-L13 by cutting at only one side (3832 bp), while it cuts VEGF-
E-L1 twice (2601 bp, 1231 bp). This indicates that the mutation of loop-3 in VEGF-E was 
successful. For the restriction enzyme Afl III no difference was observed between this 
two VEGF-E-loop-mutants. This enzyme was only used to exclude all sorts of 
unreasonable mutants.  
The clone S3 shows the expected restriction pattern. The correct sequence of clone 3 
was confirmed by DNA sequencing (Microsynth). 
 
 
 
M3          S1           S2            S3           S4          S5         L1
Afl III Eco24I
3832
2046
1459
2601
1231
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Restriction digest of VEGF-E-L13. This picture of an 1% agarose-gel shows the result of a 
restriction digest of different presumable VEGF-E-L13 clones with the restriction enzymes Afl III and 
Eco24I. Clone S3 shows the expected restriction pattern: it was cleaved twice with the enzyme Afl III 
(bands of 2046 bp and 1459 bp) and once with Eco24I (3832 bp) 
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4.1.2 Protein expression and purification 
4.1.2.1 Nickel affinity chromatography 
 
Small-scale expression was performed to select for high-expression clones. Out of a 
100 ml test expression (P. pastoris) 2 mg of pure protein were obtained. The purified 
protein was analyzed by SDS-PAGE. VEGF-E-L13, which forms a disulfide linked 
homodimer in solution, was detected as a clear band at about 15 kDa under reducing 
condition and at about 30 kDa under non-reducing conditions (Figure 4). The 
fractions containing the VEGF-E-L13 were pooled and 4 ml of PBS were added to 
dilute the Imidazole concentration. The pooled fractions were then concentrated to 
15 mg/ml. The protein was used for binding analysis  
 
 
 E18 T0 T3 FT    E18 EL1 EL3
R                       NR
36
29
24
20
14
45
7
kDa
66 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Production and purification of VEGF-E-L13 by nickel affinity chromatography. Left panel R: E18 is 
one of the eluted fractions after the Ni2+-column. The protein forms a monomer of about 15 kDa under 
reducing conditions (R). Right panel: The protein forms a dimer of about 30 kDa under non-reducing 
conditions (NR). T0 is the time point before induction and T3 is the time point when the production 
was stopped (supernatant which was loaded on the column). FT (flow-through) is the fraction which 
did not bind to the column. As a control two other VEGF-E-loop-mutants were loaded on the gel (EL1 
and EL3).  
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4.1.2.2 Size exclusion chromatography (Gel filtration) 
 
The fractions containing pure VEGF-E-L13 were pooled, concentrated and purified by 
gel filtration. The protein eluted as a homogenous peak at 15.6 ml from the Superdex 
200 column, which corresponds to an apparent molecular size of about 37 kDa. The 
peak at 11.7 ml corresponds to a molecular size of about 250 kDa and most likely 
represents some oligomers of the protein.  
 
 superdex200 HR 10 DM 140705:1_UV1_280nm  superdex200 HR 10 DM 140705:1_UV2_260nm  superdex200 HR 10 DM 140705:1_UV1_280nm@01,BASEM
   0
 500
1000
1500
mAU
0.0 5.0 10.0 15.0 20.0 25.0 ml
  11.70
  15.55
  19.68
 
 
Figure 5. Size exclusion chromatography of VEGF-E-L13 on a Superdex 200 column. VEGF-E-L13 eluted as 
a homogenous peak at 15.6 ml, which corresponds to an apparent molecular size of about 37 kDa. The 
blue line shows the absorbance at 280 nm and the red line the absorbance at 260 nm. 
 
The fractions were analyzed on a 15 % SDS-PA-gel (Figure 6). The VEGF-E-L13 protein 
forms a monomer under reducing conditions, which has the size of about 15 kDa. The 
purity of the protein was high enough to proceed with crystallization experiments. 
Therefore the fractions E11-E15 were pooled and concentrated to 20 mg/ml. From a 
500 ml culture 10 mg of highly pure VEGF-E-L13 were obtained.  
 
 Inj. E3 E9 E10 E11 E12 E13 E14 E15
36
29
24
20
45
kDa
66
15
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Gel filtration of VEGF-E-L13. Coomassie-stained 15 % SDS-PA-gel showing the injected sample 
(Inj.) and the eluted fractions of VEGF-E-L13 (E3-E15) after the gel filtration.  
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4.1.3 Competitive Binding Assays 
 
Competitive binding assays were performed on PAE cells expressing either VEGFR-       
1 or -2. Binding of radiolabeled VEGF-A to VEGFR-2 was competed with VEGF-E, but 
not with the loop mutants VEGF-E-L1, VEGF-E-L3 and VEGF-E-L13 or PlGF. This shows 
that exchanging either one or both of these loops abolished binding to VEGFR-2 
(Figure 7). Interestingly, competition with the point mutant VEGF-E-R46I was more 
efficient than with the native viral protein (VEGF-E) indicating that during Orf virus 
evolution VEGF-E diverged from optimal receptor binding.  
When these mutants were tested on VEGFR-1 expressing cells, only VEGF-E-L13 
showed specific binding besides VEGF-A and PlGF. The results of these experiments 
indicate that a suitable set of the loops L1 and L3 determines receptor specifity. 
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Figure 7. Competitive Binding Assay with 0.1 mM 125I-VEGF-A on PAE cells expressing either VEGFR-1 or -2. 
Upper panel: VEGFR-1 expressing PAE cells. The VEGF-E-L13 mutant shows an affinity to VEGFR-1. 
Lower panel: VEGFR-2 expressing PAE cells. All the loop-mutants lost affinity to VEGFR-2. Competition 
with the point mutant VEGF-E-R46I was more efficient than with the wildtype VEGF-E (wt).   
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4.1.4 Crystallization of VEGF-E-L13 and preliminary X-Ray diffraction  
 
The purified and concentrated VEGF-E-L13 mutant was used to set up initial 
crystallization screens using the Crystallization Basic Kit (SIGMA) and both the 
known crystallization conditions for wildtype VEGF-E and PlGF. Four hits were 
obtained from the Sigma Kit and were used as starting conditions for further 
optimization (Figure 8 and 9, left panel). In all conditions the crystals appeared as 
thin needles or needle bundles. Extensive screens were setup to optimize crystal 
growth by varying precipitant concentration against pH, and by varying the 
temperature. However, no improvement of crystal quality could be achieved.  
 
 
 
 
24 Å
40 Å
A
B
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. First crystallization screen (SIGMA Basic Screen Kit) and X-Ray diffraction. The following 
conditions were used: for sample A 0.2 M Li-sulfate, 0.1 M Tris-HCl pH 8.5, 30 % PEG 4 K and for the 
measurements, performed on a in house X-Ray source, as cryoprotectant 5 – 20 % glycerol was added 
to the precipitant solution. For sample B the precipitant solution contained 0.1 M HEPES pH 7.5, 0.8 M 
Na-K-Tartrate and as cryoprotectant 5 – 40 % glycerol. The measurement were performed at the SLS.  
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19 Å
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Figure 9. First crystallization screen (SIGMA Basic Screen Kit) and X-Ray diffraction. The following 
conditions were used: for sample C 0.1 M Na-citrate pH 5.6, 20 % PEG 4K, 20 % Isopropanol and for 
sample D the precipitant solution contained 0.1 M HEPES pH 7.5, 20 % PEG 4K, 10 % Isopropanol. Both 
measurements were performed at the SLS.  
 
 
 
For X-Ray diffraction experiments, crystals were equilibrated stepwise in 
cryoprotectant solution if needed and flash-frozen directly in a liquid-nitrogen cryo 
stream. The measurements were performed either on a in house X-Ray source or at 
the SLS (Figure 8 and 9, right panel). Poor diffraction was observed for all the crystals. 
However, from the PEG 4K/ Isopropanol condition at pH 7.5 some reflections were 
detected up to 19 Å resolution (Figure 9 D). The PEG/ Isopropanol condition grown at 
pH 5.6 (Figure 9 C) yielded a series of rings to 20 Å resolution on the diffraction 
image, indicating a random orientation of the molecules in the crystals. However 
these results clearly indicated the presence of protein crystals.  
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4.2 VEGFR-2 
 
The VEGFR-2_D1-3-GST construct was cloned and transformed to different E.coli 
strains for expression. Test for expression and solubility were made with different 
DNA samples. The protein was purified by glutathione sepharose affinity 
chromatography. 
4.2.1 Cloning of VEGFR-2_D1-3_GST 
 
To verify the identity of different positive VEGFR-2_D1-3 clones a restriction digest 
was made. Three VEGFR-2_D1-3 clones were digested with the restriction enzymes 
Afl III and Eco24I. Compared to the template DNA (pDEST 24), which contains three 
Afl III (3069 bp, 2838 bp and 1054 bp) and two Eco24I (6947 bp and 14 bp), the 
expression clone (pDEST24_D1-3_GST) contains three Afl III restriction sites (2838 bp, 
2636 bp and 798 bp) and one Eco24I restriction site (6258 bp).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6258
2838
2636
798
1      2      3    M3M8
Afl III Eco24I
 
Figure 10. Restriction digest of VEGFR-2_D1-3_GST. This picture of an 1% agarose- gel shows the result 
of a restriction digest of different positive VEGFR-2_D1-3_GST clones. As restriction enzymes Afl III and 
Eco24I were used. The clones 2 and 3 show the expected restriction pattern: they were cleaved three 
times with the enzyme Afl III (bands of 2838 bp, 2636 bp and 798 bp) and once with Eco24I   (6258 bp). 
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4.2.2 Test of expression and solubility (Dot Blot) 
 
To find out if expression works and if the proteins are soluble or not two different 
DNA samples were transformed to two different E.coli-strains and were grown in a 
small volume culture. Cells were lysed with a chemical method, applied on a PVDF-
membrane (Dot Blot) and detected with α-GST-antibodies.  
 
Sample 1                Sample 2
BL21(DE3)
B834(DE3)
T              S            T              S 
 
 
 
 
 
 
 
 
 
 
Figure 11. Expression and solubility screen with two VEGFR-2_D1-3-GST-DNA samples. There are two 
different VEGFR-2_D1-3-DNA samples transferred to two different E.coli-strains. The expression test 
shows that both of this E.coli-strains express the protein and there is a lot of soluble protein.  
 
 
The expression and solubility test showed that expression occurred and that most of 
the protein is soluble. However, no conclusion could be drawn whether the signal 
was generated by the intact fusion protein of interest, or by fragments or other 
proteins (Figure 11). Western blot analysis of the same samples showed that the 
signal was caused by degradation products of the protein (Figure 12).  
 
To better control the time of induction and the protein degradation a small-scale 
expression was performed. Expression was induced with IPTG and samples were 
taken every hour for Western Blot analysis (Figure 12). A signal for the full-length 
fusion protein of about 60 kDa was only detectable after 2 hours induction. Longer 
induction time resulted in no signal for the full length protein.  
 
 
 
T0        T2        T3        T5
T    S     T     S     T     S     T    S
~60 kDa
~30 kDa
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12. Western Blot with different time points after small-scale expression of VEGFR-2_D1-3_GST in 
E.coli (BL21pLysS (DE)). The full-length fusion protein of about 60 kDa is only detectable after 2 hours 
induction. Later time point show only the degradation products.  
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4.2.3 Protein expression and Purification of VEGFR-2_D1-3-GST 
 
A large-scale production of VEGFR-2_D1-3-GST was performed following the results 
from the small-scale expression. Protein purification was performed by glutathione 
sepharose (affinity chromatography) and the eluted fractions were analyzed on a 
10% SDS-PA-gel (Figure 13).  
For the whole protein (D1-3 and GST-tag) a molecular size of about 60 kDa was 
expected. None of these fractions showed a band in this range, but all of them 
contained degradation products in the range of about 30 kDa.  
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Figure 13. Production and purification of VEGFR-2_D1-3_GST by Glutathione sepharose. Left: 10 % SDS-
PA-gel as a result of the production and purification of VEGFR-2_D1-3_GST out of 1000 ml culture 
(E.coli). T0 time point before inducing expression, lys =lysate, f.t. = flow through, W = wash fraction 
and F6-F12 are the eluted fractions. Right: On this 10 % SDS-PA-gel there is one of the eluted fractions 
after glutathione sepharose column to see and as a control the GST-protein. 
 
 
All three degradation products are in a range of about 30 kDa. Since this is half the 
size of the expected full-length fusion protein, the question arose, whether two of 
the three bands would contain the two halfs of the molecule. Therefore the three 
bands were plotted on a PVDF-membrane, stained by Amidoblack and sent for 
Edman-Sequencing. The sequencing was only possible for the upper band (MKKFLST) 
which contained the 43 C-terminal residues of domain 3 fused to GST. The middle 
band was blocked, and the lowest band could not be sequenced.  
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5 DISCUSSION 
 
The aim of the diploma thesis was to generate the loop chimera VEGF-E-L13, to 
characterize its binding properties to VEGFR-1 and –2 and to crystallize the mutated 
protein. This protein was designed based on the observed differences in the loop 
regions 1 and 3 between the crystal structures of VEGF-E and PlGF with the aim to 
clarify the role of these loops in receptor VEGFR-specificity.  
Cloning was performed by SiteDirected Mutagenesis using a VEGF-E-L1 mutant as 
template. The yeast Pichia pastoris was chosen as expression system as it has been 
successfully used for the expression of related VEGF’s in the lab. The protein was 
designed with a cleavable aminoterminal hexahistidine tag to allow a simple two 
step purification by nickel affinity and size exclusion chromatography.  
For competitive binding assays the nickel affinity purified protein was used. 
Competitive binding assays on PAE cells expression either VEGFR-1 or –2 with 
radiolabeled VEGF-A164 were performed with the VEGF-E-L13, with the individual loop 
mutants L1 and L3, and the point mutant VEGF-E-R46I, which were cloned in the 
course of my semester thesis. Binding of the radiolabeled VEGF-A to VEGFR-2 was 
competed with VEGF-E, but not with the loop mutants VEGF-E-L1, VEGF-E-L3, VEGF-E-
L13 or PlGF. Competition with the point mutant VEGF-E-R46I was more efficient than 
with the native viral protein (VEGF-E) yet did not establish binding to VEGFR-1, 
suggesting that Arg46 does not directly regulate interaction with VEGFR-1, but is 
critical for proper binding to VEGFR-2. An important finding of this studies showed 
the results of VEGF-E-L13 mutant: if both loops of VEGF-E were exchanged by 
sequences from PlGF binding to VEGFR-2 got lost but the mutant bound, although 
with lower affinity than VEGF-A and PlGF, to VEGFR-1. This indicates that L1 and L3 
interact which each other and that the relative orientation between L1 and L3 
determines VEGFR-specificity.  
To know more about the orientation of these two loops crystallization of VEGF-E-L13 
was performed. The purified and concentrated VEGF-E-L13 mutant was used to set 
up initial crystallization screens using the Crystallization Basic Kit (SIGMA) and both 
the known crystallization conditions for wildtype VEGF-E and PlGF. Four hits were 
obtained from the Sigma Kit and were used as starting conditions for further 
optimization. For X-Ray diffraction experiments, these crystals were equilibrated 
stepwise in cryoprotectant solution and flash-frozen directly in a liquid-nitrogen cryo 
stream. The measurements were performed either on a in house X-Ray source or at 
the SLS. Because these crystals were very small they only diffracted to low resolution.  
To get bigger crystals the four conditions of the Sigma Kit were optimized by varying 
the pH, precipitant concentration and temperature. These optimization attempts 
resulted either in large amounts of phase separation in the drops or in very thin 
needles. Apparently the protein is prone to preferentially grow in one dimension. To 
avoid phase separation an additive screen using 24 different detergents was set up, 
however, little improvement was achieved. Triton-X100 showed the best results, so it 
would be advisable to perform all purification steps and repeat the Sigma basic 
screen in the presence of Triton-X100.  
Microseeding experiments were also performed to improve crystal quality. 
Therefore, a 2 µl drop containing VEGF-E-L13 needles was homogenized with a small 
glass rod to prepare a seed stock. These seeds were added to a freshly prepared 
crystallization drop to induce crystal growth. However, no crystals could be grown 
from these setups. 
The purified VEGF-E-L13 protein contained an N-terminal His-tag which most likely 
effected the proper crystallization of the protein. In a future experiment it would be 
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advisable to remove the tag before setting up crystallization to see if differences 
could be observed in crystal growth.  
 
To understand the specific interaction of VEGF-receptors with their ligands, the 
crystal structures of receptor-ligand complexes are needed in addition to the 
structural information about the individual ligands. An optional project for this 
diploma thesis was to clone a VEGFR-2 fragment that contains the first three Ig-
domains fused to a GST for future co-crystallization of ligand-receptor complexes. 
Expression of selected VEGFR domains in eukaryotic systems is in progress in the lab, 
however low yields of expressed protein are obtained and production time is much 
longer compared to E. coli. The aim of this additional project was to assess E. coli as 
an alternative expression system for fast production of suitable amounts of protein 
that could be used for complex formation either with the wildtype ligands VEGF-E or 
VEGF-A, or with the mutant VEGF-E-R46I. 
Expression and solubility tests were made with positive transformants in different 
E.coli strains. The results of the dot blots indicated the presence of good amounts of 
protein in the soluble form, but did not allow any conclusion about the integrity of 
the expressed protein. Additional analysis by SDS-PAGE and Western Blot revealed 
that proteolytic degradation occurred during expression: Three fragments in the 
range of 30 kDa were detected instead of the expected 60 kDa. Only the largest of 
these three fragments could be sequenced (Edman-Sequencing) and corresponded 
to the carboxyterminal 43 residues of VEGFR-2-domain 3 fused to GST. Based on a 
homology model of domain 3 the cleavage occurred in the middle of a β-sheet, 
indicating that the protein most likely was not proper folded and therefore more 
sensitive to proteases. Clearly more expression tests in different E.coli strains with 
different genotypes need to be performed, to find a strain that shows less 
degradation. Alternatively the known cleavage sites could be mutated by site 
directed mutagenesis. Since we do not know how many cleavage sites are present 
upstream the MKKFLST, this would only be considered in case no more or only a few 
cleavage sites are present. 
Many other approaches could be tested, e.g. including an additional tag at the amino 
terminus, trying different tags, production in inclusion bodies and refolding. 
However, this case clearly demonstrates that E.coli is not always suitable for protein 
expression, although it is fast, easy to handle and cheaper than eukaryotic 
expression systems. 
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6 ABBREVIATIONS 
 
AP Alkaline phosphatase 
BCIP 5-Bromo-4-Chloro-3-Indolylphosphatyl-p-Toluidine Salt 
BSA Bovine Serum Albumine 
BMGY Buffered Glycerol-complex Medium 
BMMY Buffered Methanol-complex Medium 
c.p.m. counts per minute 
DTT Dithiothreitol 
EDTA Ethylenediaminetetraacetic acid 
IPTG Isopropyl-beta-D-thiogalactopyranoside 
LB Luria-Bertani media 
MEM Minimal essential medium 
MWCO Molecular weight cut off 
NBT Nitro-blue Tetrazolium Chloride 
PAE Porcine aortic endothelial  
PAGE Polyacrylamid Gel Electrophoresis 
PBS Phosphate Buffered Saline 
PEG Polyethylene Glycol 
PMSF Phenylmethylsulphonylfluoride 
RT Room temperature 
SDS Sodium Dodecyl Sulfate 
VEGF Vascular Endothelial Growth Factor 
VEGFR Vascular Endothelial Growth Factor Receptor 
YPD Yeast Extract Peptone Dextrose Medium 
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